Skip to main content
Log in

What we have learned from the myriad trials

  • What We Have Learned from the Myriad Trials
  • Published:
JNHA - The Journal of Nutrition, Health and Aging

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.


  1. Wilcock GK, Black SE, Hendrix SB, Zavitz KH, Swabb EA, Laughlin MA, Tarenflurbil Phase 11 Study investigators. Efficacy and safety of tarenflurbil in mild to moderate Alzheimer’s disease: a randomised phase 11 trial. Lancet Neurol. 2008 Jun;7(6):483–493.

    Article  PubMed  CAS  Google Scholar 

  2. Folstein MF, Folstein SE, McHugh PR. “Mini-mental state”. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975; 12:189–198.

    Article  PubMed  CAS  Google Scholar 

  3. Green R, Schneider L, Hendrix S, Zavitz K, Swabb E. “03-04-01: Safety and efficacy of tarenflurbil in subjects with mild Alzheimer’s disease: Results from an 18-month multi-center phase 3 trial.” Alzheimer Dement 2008; 4, T165 (abstr).

    Article  Google Scholar 

  4. Rosen WG, Mohs RC, Davis KL. A new rating scale for Alzheimer’s disease. Am J Psychiatry 1984; 141:1356–1364.

    PubMed  CAS  Google Scholar 

  5. Mohs RC, Knopman D, Petersen RC, et al. Development of cognitive instruments for use in clinical trials of antidementia drugs: additions to the Alzheimer’s disease assessment scale that broaden its scope. The Alzheimer’s Disease Cooperative Study. Alzheimer Dis Assoc Disord 1997; 11(suppl 2): S13–21.

    PubMed  Google Scholar 

  6. Galasko D, Bennett D, Sano M, et al. An inventory to assess activities of daily living for clinical trials in Alzheimer’s disease. The Alzheimer’s Disease Cooperative Study. Alzheimer Dis Assoc Disord 1997; 11(suppl 2): S33–39.

    Article  PubMed  Google Scholar 

  7. Hughes CP, Berg L, Danziger WL, Coben LA, Martin RL. A new clinical scale for the staging of dementia. Br J Psychiatry 1982; 140: 566–572.

    Article  PubMed  CAS  Google Scholar 

  8. Jackson M, Hendrix S, Zavitz K, Green R, Schneider L, Swabb E. P4–376: A phase 3 multicenter trial of tarenflurbil in subjects with mild dementia of the Alzheimer’s type (Act-Earli-AD): Rationale and methodology. Alzheimer Dement 2008, 4, T784 (abstr).

    Article  Google Scholar 

  9. Hendrix S, Gutin A, Zavitz K, Carron G, Laughlin M, Horton S. Modification of the staggered start and randomized withdrawal clinical trial designs: toward a practical demonstration of disease modification in Alzheimer’s disease (AD). Alzheimer Dement 2007; 3:S160 (abstr).

    Article  Google Scholar 

  10. Chuang-Stein C. Seize the opportunities Pharmaceutical Statistics 2004; 3, 157–159

    Google Scholar 

  11. Pocock S, White I. Trials stopped early: too good to be true? Lancet 1999; 353(9157):943–944.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations


Corresponding author

Correspondence to S. B. Hendrix.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Hendrix, S.B., Wilcock, G.K. What we have learned from the myriad trials. J Nutr Health Aging 13, 362–364 (2009).

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: